Overview
Uvera is developing a natural UV protective ingredient that is safe for human health and environmentally friendly, targeting the full spectrum of UV sun radiation. The company focuses on using biotechnology to create alternatives to harmful chemical sunscreens that can damage coral reefs and human health.
Financials
Revenue history (in k)
Financial insight
- Possible Estonian CIT: Equity includes Art. 28d line items, but all amounts are 0 — this may be an accounting template or the first year of the regime.
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2018-12-22. Active
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
6 public aid cases recorded, with a total value of $349,180.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Dec 5, 2024 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $23,352 | PREZYDENT MIASTA GDYNIA | |
| Dec 5, 2024 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $14,689 | PREZYDENT MIASTA GDYNIA | |
| Dec 5, 2024 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $12,658 | PREZYDENT MIASTA GDYNIA |
European Funds
2 projects recorded: 1 from FE lists ($71,814) and 1 Commission grant (FTS) ($2,841,585).
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2020-10-01 | 101009401 - Uvera - safe and natural uv skin protection | $2,841,585 | 1.1.31 - Horizon 2020 | |
| 2020-05-16 | Opracowanie wniosku o Eurogrant planowanego do złożenia przez UVera S.A. w ramach konkursu EIC Accelerator. | $71,814 | Program Operacyjny Inteligentny Rozwój |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
In the case of a multi-member management board, each member of the management board acting independently is authorized to make declarations of will on behalf of the company and represent the company.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Adam Kiciak (50)  | Shareholder of a joint-stock company, 42.57% |
Competitors
| Name | Revenue | Website | |
|---|---|---|---|
| Centrum Badań Weterynaryjnych Vetcomplexsp. z o.o. | $255,522.81 | vetcomplex.pl | |
| VASA Therapeuticssp. z o.o. | $216,535.01 | vasatherapeutics.com | |
| Phage Consultantssp. z o.o. | $193,130.82 | phageconsultants.com | |
| Bactremsp. z o.o. | $181,958.36 | bactrem.pl | |
| FcbiotechS.A. | $148,945.77 | fcbiotech.pl | |
| Innervisionsp. z o.o. | $132,625.90 | innervision.pl | |
| AI Corelabsp. z o.o. | $128,365.55 | aicorelab.com | |
| Relvosp. z o.o. | $120,693.26 | relvo.pl | |
| Microblicsp. z o.o. | $122,383.50 | microblic.pl | |
| Biodecsp. z o.o. | $115,508.63 | biodec.pl |
Change history
| Date | Event |
|---|---|
| 2022-01-14 | Share capital change (162,265.00 PLN → 180,850.00 PLN) |
| 2020-09-29 | Share capital change (141,100.00 PLN → 162,265.00 PLN) |
| 2018-12-12 | Entered in the register |
FAQ
Last updated: 2026-03-29